Evidence map›Paper›PMID 40882679›Full record

ArticleTherapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy2025

Cell-Free and Concentrated Ascites Reinfusion Therapy (CART) Shows Enhanced Efficacy in Gynecological Cancer Patients: A Post-Marketing Surveillance Study.

Nami Tamura, Takashi Hirayama, Emiko Yoshida, Junna Terao, Misato Kawata, Kengo Hiranuma, Toshiyuki Okumura, Kazunari Fujino, Naoko Torii, Noriko Soneda and 4 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Cell-Free and Concentrated Ascites Reinfusion Therapy (CART) Shows Enhanced Efficacy in Gynecological Cancer Patients: A Post-Marketing Surveillance Study.Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Nami TamuraDepartment of Obstetrics and Gynecology, Juntendo University, Tokyo, Japan.ORCID https://orcid.org/0009-0001-4235-6780
Takashi HirayamaDepartment of Obstetrics and Gynecology, Juntendo University, Tokyo, Japan.ORCID https://orcid.org/0000-0001-5993-6688
Emiko YoshidaDepartment of Obstetrics and Gynecology, Juntendo University, Tokyo, Japan.ORCID https://orcid.org/0000-0002-8249-490X
Junna TeraoDepartment of Obstetrics and Gynecology, Juntendo University, Tokyo, Japan.
Misato KawataDepartment of Obstetrics and Gynecology, Juntendo University, Tokyo, Japan.
Kengo HiranumaDepartment of Obstetrics and Gynecology, Juntendo University, Tokyo, Japan.ORCID https://orcid.org/0000-0001-8197-4031
Toshiyuki OkumuraDepartment of Obstetrics and Gynecology, Juntendo University, Tokyo, Japan.
Kazunari FujinoDepartment of Obstetrics and Gynecology, Juntendo University, Tokyo, Japan.
Naoko ToriiAsahi Kasei Medical Co. Ltd., Tokyo, Japan.
Noriko SonedaAsahi Kasei Medical Co. Ltd., Tokyo, Japan.
Go MurayamaDepartment of Internal Medicine and Rheumatology, Juntendo University, Tokyo, Japan.
Makio KusaoiDepartment of Internal Medicine and Rheumatology, Juntendo University, Tokyo, Japan.ORCID https://orcid.org/0000-0003-0064-4765
Ken YamajiDepartment of Internal Medicine and Rheumatology, Juntendo University, Tokyo, Japan.
Yasuhisa TeraoDepartment of Obstetrics and Gynecology, Juntendo University, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAscites management is crucial for gynecological cancer patients requiring long-term treatment. Cancer type-specific differences may influence CART outcomes, but comparative data remain limited. This study evaluated CART efficacy in gynecological versus other cancers.

methodsThis subgroup analysis included 125 cancer patients undergoing 296 CART sessions at 22 Japanese centers (2014-2015). Patients were divided into gynecological cancer (Group G, n = 46) and other cancer groups (Group O, n = 79).

resultsGroup G had significantly higher concurrent chemotherapy rates (41.2% vs. 12.3%, p < 0.001) and ascitic protein/albumin concentrations. Group G showed significant renal function improvements: decreased serum creatinine (0.7 ± 0.3 to 0.6 ± 0.3 mg/dL, p < 0.001), decreased BUN (17.9 ± 8.7 to 14.5 ± 9.0 mg/dL, p < 0.001), and increased eGFR (72.7 ± 24.8 to 81.3 ± 27.6 mL/min/1.73 m

conclusionCART demonstrates enhanced efficacy in gynecological cancer patients, particularly improving renal function, potentially reducing chemotherapy-related toxicity, and improving treatment tolerability.

Indexed as

AscitesGenital Neoplasms, FemaleAdultAgedAntineoplastic AgentsFemaleHumansJapanMiddle AgedProduct Surveillance, PostmarketingRetrospective StudiesTreatment OutcomeAntineoplastic Agentscell‐free and concentrated ascites reinfusion therapy (CART)gynecological cancerpost‐marketing surveillance (PMS)

Identifiers

PMID40882679
PMCPMC12586275

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.